Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-γ activity

American Journal of Gastroenterology

Volumn 105, Issue 7, 2010, Pages 1595-1603

  Pedersen, Gitte ^a   Brynskov, Jørn ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOPHILIN; ENEMA; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; COLON MUCOSA; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ACTIVITY; EPITHELIUM CELL; EVENING DOSAGE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TREATMENT DURATION; ULCERATIVE COLITIS;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; BLOTTING, WESTERN; COLITIS, ULCERATIVE; COLONOSCOPY; ENEMA; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MESALAMINE; MIDDLE AGED; PEPTIDES; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES;

EID: 77954425357     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.749     Document Type: Article

References (43)

1. Dubuquoy L, Rou sseaux C, Turu X et al.P P A R γ as a new therapeutic target in inf ammator y bowel diseases. Gut 2006; 55:1341-1349
2. Chinetti G, Fruchart JC, Staels B. Peroxiso me pro liferato r-activated receptors (PPARs):nuclear receptors at the crossroads between lipid metabolism and infammation. Infamm Res 2000; 49:497-505.
3. Su W, Bush CR, Necela BM et al. Dif erential expression, distribution, and function of PPAR-gamma in the proximal and distal colon. Physiol Genomics 2007;30:342-353
4. Altmann R, Hausmann M, Spottl T et al. 13-Oxo-ODE is an endogenous ligand for PPARy in human colonic epithelial cells. Biochem Pharmacol 2007;74:612-622 (Pubitemid 47042013)
5. Welch JS, Ricote M, Akiyama TE et al. PPARy and PPAR8 negatively regulate specific subsets of lipopolysaccharide and IFN-y target genes in macrophages. Proc Natl Acad Sci USA 2003;100:6712-6717
6. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte infammatory cytokines. Nature 1998;391:82-86
7. Ponferrada A, Caso JR, Alou L et al. The role of PPARy on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 2007;132:1791-1803
8. Ricote M, Li AC, Willson TM et al. The peroxisome proliferator-activated recep-tor-yis a negative regulator of macrophage activation. Nature 1998;391:79-82.
9. Desreumaux P, Dubuquoy L, Nutten S et al. Attenuation of colon inf ammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor y (PPARy) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-838
10. Saubermann LJ, Nakajima A, Wada K et al. Peroxisome proliferator- activated receptor gamma agonist ligands stimulate a T 2 cytokine response and prevent acute colitis. Infamm Bowel Dis 2002;8:330-339
11. Adachi M, Kurotani R, Morimura K et al. Peroxisome proliferator activated receptor y in colonic epithelial cells protects against experimental inf ammatory bowel disease. Gut 2006; 55:1104-1113
12. Yamamoto K, Ninomiya Y, Iseki M et al. 4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor y agonist alleviates the symptoms of DSS-induced colitis. Biochem Biophys Res Commun 2008;367:566-572
13. Katayama K, Wada K, Nakajima A et al. A novel PPAR y gene therapy to control inf ammation associated with inf ammatory bowel disease in a murine model. Gastroenterology 2003; 124:1315-1324
14. Ramakers JD, Verstege MI, Tuijls G et al. The PPARy agonist rosiglitazone impairs colonic infammation in mice with experimental colitis. J Clin Immunol 2007;27:275-283
15. Dubuquoy L, Jansson EA, Deeb et al. Impaired expression of peroxisome proliferator-activated receptor y in ulcerative colitis. Gastroenterology 2003;124:1265-1276
16. Wu GD. Is there a role for PPARy in IBD? Yes, no, maybe. Gastroenterology 2003;124:1538-1542
17. Lewis JD, Lichtenstein GR, Deren JJ et al. Rosiglitazone for active ulcerative colitis: A randomized placebo-controlled trial. Gastroenterology 2008;134:688-695
18. Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 2008; 14:114-119
19. Nissen SE, Wolski K. Ef ect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471
20. Editorial, The Lancet. Rosiglitazone no longer recommended. Lancet 2009 372 1520.
21. Langholz E, Munkholm P, Davidsen M et al. Course of ulcerative colitis:analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
22. Pedersen G, Saermark T, Giese B et al. A simple method to establish short-term cultures of normal human colonic epithelial cells from endoscopic biopsy specimens. Comparison of isolation methods, assessment of viability and metabolic activity. Scand J Gastroenterol 2000; 35:772-780
23. Brynskov J, Foegh P, Pedersen G et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inf ammatory bowel disease. Gut 2002; 51:37-43.
24. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 1991; 19:3998.
25. Gupta RA, Brockman JA, Sarraf P et al. Target genes of peroxisome proliferator-activated receptor y in colorectal cancer cells. J Biol Chem 2001;276:29681-29687
26. Matthiessen MW, Pedersen G, Albrektsen T et al. Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 2005;40:198-205.
27. Pedersen G, Saermark T, Bendtzen K et al. Cultures of human colonic epithelial cells isolated from endoscopical biopsies from patients with inf ammatory bowel disease. Efect of IFNy, TNFa and IL-1P on viability, butyrate oxidation and IL-8 secretion. Autoimmunity 2000; 32:255-263
28. D'Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efcacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132:763-786
29. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625-1629
30. Gupta RA, Dubois RN. Controversy:PPARy as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2002; 283:G266-9.
31. Perner A, Andresen L, Pedersen G et al. Superoxide production and expression of NAD(P)H oxidases by transformed and primary human colonic epithelial cells. Gut 2003;52:231-236
32. Pedersen G, Andresen L, Matthiessen MW et al. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol 2005;141:298-306.
33. Lefebvre AM, Chen I, Desreumaux P et al. Activation of the peroxisome proliferator-activated receptor y promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4:1053-1057
34. Lefebvre M, Paulweber B, Fajas L et al. Peroxisome proliferator-activated receptor gamma is induced during dif erentiation of colon epithelium cells. J Endocrinol 1999;162:331-340
35. Chong HC, Tan MJ, Philippe V et al. Regulation of epithelial- mecenchymal IL-1 signaling by PPARp/8 is essential for skin homeostasis and wound healing. J Cell Biol 2009;184:817-831
36. Wada K, Nakajima A, Blumberg RS. PPARy and inf ammatory bowel disease: A new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 2001;7:329-331
37. Tanaka T, Itoh H, Doi K et al. Downregulation of peroxisome proliferator-activated receptor y expression by inf ammatory cytokines and its reversal by thiazolidinediones. Diabetologia 1999;42:702-10.
38. Kim MS, Sweeney TR, Shigenaga JK et al. Tumor necrosis factor and interleukin 1 decrease RXRa, PPARa, PPARy, LXRa, and the coactivators SRC-1, PGC-1a, and PGC-1fS in liver cells. Metabolism 2007;56:267-279
39. Sung CK, She H, Xiong S et al. Tumor necrosis factor-a inhibits peroxisome proliferator-activated receptor y activity at a posttranslational level in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2004; 286:G722-9.
40. Waite KJ, Floyd ZE, Arbour-Reily P et al. Interferon-y-induced regulation of peroxisome proliferator-activated receptor y and STATs in adipocytes. J Biol Chem 2001;276:7062-7068
41. Reinecker HC, Stefen M, Witthoef T et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1P by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-181
42. Brynskov J, Tvede N, Andersen CB et al. Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inf ammatory bowel disease. Gut 1992;33:55-58
43. Regueiro M, Lofus EV Jr, teinhart AH et al. Clinical guidelines for the medical management of lef -sided ulcerative colitis and ulcerative proctitis:summary statement. Infamm Bowel Dis 2006;12:972-978